139 related articles for article (PubMed ID: 16538217)
1. Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer.
Kubben FJ; Sier CF; van Duijn W; Griffioen G; Hanemaaijer R; van de Velde CJ; van Krieken JH; Lamers CB; Verspaget HW
Br J Cancer; 2006 Apr; 94(7):1035-40. PubMed ID: 16538217
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer.
Alakus H; Grass G; Hennecken JK; Bollschweiler E; Schulte C; Drebber U; Baldus SE; Metzger R; Hölscher AH; Mönig SP
Histol Histopathol; 2008 Aug; 23(8):917-23. PubMed ID: 18498066
[TBL] [Abstract][Full Text] [Related]
3. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma.
Sier CF; Kubben FJ; Ganesh S; Heerding MM; Griffioen G; Hanemaaijer R; van Krieken JH; Lamers CB; Verspaget HW
Br J Cancer; 1996 Aug; 74(3):413-7. PubMed ID: 8695357
[TBL] [Abstract][Full Text] [Related]
4. MMP-2 as a putative biomarker for carcinomatosis in gastric cancer.
Noh S; Jung JJ; Jung M; Kim TS; Park CH; Lim SJ; Jeung HC; Cheol H; Chung HC; Rha SY
Hepatogastroenterology; 2011; 58(112):2015-9. PubMed ID: 22024074
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids of patients with temporomandibular joint osteoarthritis.
Kanyama M; Kuboki T; Kojima S; Fujisawa T; Hattori T; Takigawa M; Yamashita A
J Orofac Pain; 2000; 14(1):20-30. PubMed ID: 11203734
[TBL] [Abstract][Full Text] [Related]
7. [Relationship of expression unbalance of matrix metalloproteinase and tissue inhibitor of metalloproteinase to invasiveness and metastasis in gastric carcinomas].
Li L; Zhang S; Lin H; Lin JY
Ai Zheng; 2002 Mar; 21(3):305-10. PubMed ID: 12452001
[TBL] [Abstract][Full Text] [Related]
8. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas.
Nomura H; Fujimoto N; Seiki M; Mai M; Okada Y
Int J Cancer; 1996 Feb; 69(1):9-16. PubMed ID: 8600068
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
Baker EA; Bergin FG; Leaper DJ
Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer.
Hilska M; Roberts PJ; Collan YU; Laine VJ; Kössi J; Hirsimäki P; Rahkonen O; Laato M
Int J Cancer; 2007 Aug; 121(4):714-23. PubMed ID: 17455256
[TBL] [Abstract][Full Text] [Related]
12. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
13. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
14. Coexpression of Matrix Metalloproteinase-7 and Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Biomarker in Gastric Cancer.
Zhang Y; Qin L; Ma X; Wang Y; Wu Y; Jiang J
Dis Markers; 2020; 2020():8831466. PubMed ID: 33005257
[TBL] [Abstract][Full Text] [Related]
15. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
17. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
18. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution.
Wu CY; Wu MS; Chiang EP; Chen YJ; Chen CJ; Chi NH; Shih YT; Chen GH; Lin JT
Clin Cancer Res; 2007 Apr; 13(7):2054-60. PubMed ID: 17404086
[TBL] [Abstract][Full Text] [Related]
19. Comparative expression of matrix metalloproteinases in internal malignancies and paired cutaneous metastatic lesions.
Kim TH; Jung JY; Roh HJ; Chung KY; Roh MR
Am J Dermatopathol; 2015 May; 37(5):381-8. PubMed ID: 25062266
[TBL] [Abstract][Full Text] [Related]
20. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
